In 1866 people with Lynch syndrome, neither 100 mg nor 300 mg daily aspirin formally met non-inferiority to 600 mg for Lynch syndrome cancers (100 mg ITT HR 0·97, 95% CI 0·67–1·42), but bleeding SAEs were 0%, 0·5% and 1·5% respectively.
RCTn = 1,879
Burn et al. Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial